, 1985) However, the same treatment protocol also demonstrated a

, 1985). However, the same treatment protocol also demonstrated an inconsistent reduction of clinical signs and the inability to eliminate faecal egg shedding, despite consecutive doses ( King et al., 1990 and Baan et al., 2011). A recent report has described the usefulness of moxidectin (2.5 mg/kg) in inducing clinical recovery and negative faecal results, along with prevention of re-infection for four consecutive months, in a dog infected by C. boehmi ( Veronesi et al., 2013). The present results confirm that a single administration of spot-on moxidectin is a suitable choice Dasatinib for the effective treatment of canine nasal capillariosis. In fact, in the present trial only

one dog remained infected after a single administration of the molecule, although this did succeed in treating the parasitic infection after a second dose. Interestingly, this dog showed the highest pre-treatment EPG Vorinostat cell line values in Group T, thus suggesting that two administrations are necessary to clear the infection in animals which may be heavily infected. Although preliminary, the present study has

filled gaps in the knowledge of treatment of canine nasal capillariosis by evaluating moxidectin in a case series of infected dogs. Apart from its high level of efficacy, Advocate® also has the advantages of single-dose administration and easy-to-apply topical delivery as compared to other molecules (e.g. fenbendazole) which require consecutive Sclareol administrations. In conclusion, Advocate® spot-on in dogs naturally infected by E. boehmi is a safe and effective option for treating clinical signs and eliminating egg shedding and adult parasites in situ. GCP studies are warranted to further evaluate the efficacy and safety of Advocate® in the therapy of canine infection with C. boehmi. These studies could also be worthwhile in terms of preventing the disease, given that infected dogs are at high and frequent risk of recurrent infections ( King et al., 1990, Baan et al., 2011 and Veronesi et al., 2013). Bayer Animal Health GmbH, Germany, provided financial support for

this study. The Authors declare that there were no competing interests and that the conceptual design, the conduct, the interpretation of results and all scientific aspects of the study were not influenced by any third party. The Authors are grateful to the veterinarians Enrico Bottero for his technical support in the rhinoscopic procedures and Silvana Meloni for her field assistance. The Authors also thank all owners and kennels that allowed their animals to participate in the trial. “
“The publisher regrets that in the above referenced article the author names were represented incorrectly. They are now reproduced correctly above. “
“Coccidiosis, caused by protozoan parasites belonging to the genus Eimeria, is one of the commonest and most economically important enteric diseases of chickens’ worldwide ( Shirley et al., 2005). Seven Eimeria species can infect the chicken (viz.

Comments are closed.